Clinical Trials
Company announces plan for registration-directed clinical trials for Ceflatonin
Published in Cancer Weekly, August 16th, 2005
The initiation of the first of two registration-directed phase II/III trials is scheduled for the third quarter of 2005. The first trial will target chronic myeloid leukemia (CML) accelerated phase patients who are resistant to high-dose Gleevec. The single-agent, phase II/III trial will initially be conducted in 6 European cancer centers, and is expected to expand to incorporate cancer centers in the U.S. in Q1, 2006.
The...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2005-08-16)
More Articles from Cancer Weekly
- Cognitive Science
Cancer listed as risk factor for long-term cognitive deficits and dementia - Coping Strategies
Social support and hopelessness examined in Turkish cancer patients - Drug Development
Continuous toxicity monitoring advised in oncologic phase II trials - Epidemiology
Correctable sources of disparities in cancer among minority elders identified - Prostate Cancer
Pilot study aimed to determine support during pre-treatment of prostate cancer - Actin
SPECs examined, role in synapse F-actin accumulation clarified - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
